Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 309,268 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 309,268 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $21.28, for a total transaction of $6,581,223.04. Following the sale, the director directly owned 1,016,633 shares of the company’s stock, valued at $21,633,950.24. This represents a 23.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 4.5%

Shares of NASDAQ DYN traded up $0.95 during midday trading on Tuesday, reaching $22.21. The stock had a trading volume of 2,510,326 shares, compared to its average volume of 2,105,434. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -6.90 and a beta of 1.09. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The company’s 50 day moving average price is $18.52 and its 200 day moving average price is $18.12.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business earned ($1.05) earnings per share. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics in the 1st quarter worth $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC increased its position in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after acquiring an additional 1,440 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Finally, TD Cowen started coverage on Dyne Therapeutics in a research note on Friday. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.